synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma is an aggressive cancer invariably associated with a chromosomal translocation involving genes encoding the SWI-SNF complex component SS18 and an SSX (SSX1 or SSX2) transcriptional repressor.
|
29502955 |
2018 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma (SS) is characterized by a tumour specific chromosomal translocation t(X;18) (p11;q11) which results in the formation of SYT-SSX1 fusion protein.
|
30219714 |
2018 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our analyses revealed that the primary tumor and NCC-SS1-C1 cell line harbored the SS18-SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles.
|
29450702 |
2018 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A transbronchial biopsy was performed, and immunohistochemical results as well as detection of SYT-SSX1 (SYnovial sarcoma Translocation-Synovial Sarcoma X chromosome breakpoint) transcripts resulted in a diagnosis of synovial sarcoma.
|
29455826 |
2018 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4.
|
29220290 |
2018 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The novel cell line expressing SS18-SSX1 on a human adipose-derived stromal cell background is expected to be helpful in addressing the question whether the chimeric gene alone is sufficient to trigger the formation of synovial sarcoma.
|
29025595 |
2017 |
synovial sarcoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
|
26905812 |
2016 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
|
27572315 |
2016 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
|
27572315 |
2016 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review.
|
25959879 |
2015 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ultimately, an immunohistochemical stain for TLE-1 demonstrated diffusely strong nuclear positivity and molecular studies showed the presence of the t(X; 18) SYT/SSX1 translocation confirming the diagnosis of SS.
|
24436244 |
2014 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis by reverse transcriptase polymerase chain reaction (RT-PCR) failed to identify the SYT-SSX1 or SYT-SSX2 fusion transcripts characteristic of synovial sarcoma.
|
24966982 |
2014 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
|
23716114 |
2014 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Reverse transcriptase polymerase chain reaction (RT-PCR), using the RNA from frozen neoplastic tissue of the resected specimen, detected a fusion gene called SYT-SSX1, specific for SS.
|
23910174 |
2013 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The increase of NCOA3 is essential for SYT-SSX1-mediated synovial sarcoma formation.
|
21454665 |
2011 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that siRNA targeting of SS18-SSX1 has therapeutic potential for the treatment of SS.
|
20198325 |
2010 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
LHGDN |
Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
|
18267106 |
2008 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that siRNA targeting of SS18-SSX1 may have therapeutic potential in the treatment of synovial sarcomas.
|
18714179 |
2008 |
synovial sarcoma
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Our results demonstrate that siRNA targeting of SS18-SSX1 may have therapeutic potential in the treatment of synovial sarcomas.
|
18714179 |
2008 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The t(X;18)(p11.2;q11.2), which results in fusion of the SYT gene at 18q11 with the SSX1, SSX2, or (rarely) SSX4 gene is a primary genetic event in 90% of SS.
|
17175375 |
2007 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis by reverse transcriptase polymerase chain reaction failed to identify the SYT-SSX1 or SYT-SSX2 fusion transcripts characteristic of synovial sarcoma.
|
17707262 |
2007 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
|
17197895 |
2007 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
In conclusion, our findings demonstrate differentially expressed genes for the 2 major gene fusion variants in SS, SS18/SSX1 and SS18/SSX2, and thereby suggest that these result in different downstream effects.
|
16152617 |
2006 |
synovial sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The striking spontaneous mesenchymal to epithelial differentiation in this cancer is reminiscent of a developmental switch, but the only clue to its mechanistic basis has been the observation that most cases of synovial sarcoma with glandular epithelial differentiation (GED) contain SYT-SSX1 instead of SYT-SSX2.
|
16849535 |
2006 |
synovial sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SYT/SSX1 translocations are seen in nearly three times as many synovial sarcomas as SYT/SSX2 translocations.
|
15641030 |
2005 |